Enhance MD vs Henry Meds
Two GLP-1 desks, one scoreboard. We put Enhance MD and Henry Meds head-to-head on the published Brief Score — the same six factors, scored the same way.
Enhance MD
The verdict
Enhance MD takes this head-to-head.
Enhance MD scores 85 to 84 on our six-factor Brief Score — A transparent, tiered compounding desk that lays out every price on the ladder up front — semaglutide, tirzepatide, microdose, and a combo line — with NAD+ care sitting alongside.
That doesn't make Henry Meds a bad call — it's best for readers who want a simple, well-known flat-fee program and don't mind paying up for it. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Enhance MD | Henry Meds | |
|---|---|---|
| Brief Score | 85/100 (B) | 84/100 (B) |
| Semaglutide | $249 every 4 weeks month-to-month (13 charges a year); $212/mo only on the 12-month prepay | $249/mo |
| Tirzepatide | $329 every 4 weeks month-to-month (13 charges a year); $280/mo only on the 12-month prepay | $349/mo |
| Coverage | Not publicly listed | Multi-state |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Risingprice rising |
Enhance MD: The ladder is fully published, but its rungs are prepay blocks: $212 and $280 are the 12-MONTH rates, while month-to-month is $249 and $329 — and every plan bills every 4 weeks, so a "monthly" plan is 13 charges a year. The $112 is $212 less a dated SUMMER50 coupon, not an entry rate.
Henry Meds: Flat-fee pioneer, but its line has drifted to the higher end of the tracker.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.